Skip To Main Content
This platform is for Australian healthcare professionals only
Campus
Campus

EVENT ONE

2023 Interactive Clinical Tutorial Series

Biomarkers to manage severe asthma in clinical practice

RECORDED ON: 9 MARCH 2023

Biomarkers for severe asthma can provide prognostic (likelihood of exacerbations) and predictive (likelihood of a good response to treatment) information. Several biologic options are now available for treating patients with severe asthma, each inhibiting different aspects of the immune response driving asthma attacks. The challenge now is to find the right biologic for the right patient.

The three on-demand videos below provide insights and practical tips from Profs Ian Pavord and Peter Wark on the use of biomarkers in patients with severe asthma to guide therapeutic decision-making.

Biomarkers in clinical practice: UK perspective

Prof Ian Pavord provides a UK perspective on using biomarkers in clinical practice to manage severe asthma with two case studies. 

Biomarkers in clinical practice: Australian perspective

Prof Peter Wark provides an Australian perspective on using biomarkers in clinical practice to manage severe asthma.

Panel discussion and Q&A

Chaired by Prof Brian Oliver, Profs Ian Pavord and Peter Wark address questions from the attendees and discuss biomarkers for managing patients with severe asthma. 

Watch the 2020–2022 ADVENT and ASPIRE series developed and endorsed by Australian and international experts

At ADVENTprogram.com you can:

  • Access medical education resources
  • Review the latest science for type 2 inflammatory diseases
  • Explore your specific interests – select materials by category or topic

Login to ADVENTprogram.com

Access to ADVENTprogram.com is restricted to healthcare professionals. Registration is required to view content.

DUPIXENT (dupilumab) PBS Information: Authority Required.

Refer to PBS schedule for full authority information. Authority required for patients aged ≥12 years with: chronic severe atopic dermatitis: OR uncontrolled severe asthma.  This product is not listed on the PBS for: children 6 months to 11 years of age with severe atopic dermatitis; children 6-11 years of age with moderate to severe asthma; adults with uncontrolled chronic rhinosinusitis with nasal polyps; or adults with moderate-to-severe prurigo nodularis.

Please review the full Product Information before prescribing Dupixent (dupilumab). Please review full product Information before prescribing Dupixent (dupilumab). Full Product Information is available from Sanofi-aventis Australia pty ltd here or by contacting 1800 818 806.

â–¼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems

MAT-AU-2302085 (v1.0)  |  SEPTEMBER 2023